Trial Profile
Rebamipide for the Treatment of Xerostomia in Sjögren Syndrome
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 04 Mar 2022
Price :
$35
*
At a glance
- Drugs Rebamipide (Primary)
- Indications Sjogren's syndrome
- Focus Therapeutic Use
- 27 Mar 2020 Planned primary completion date changed from 1 Mar 2013 to 1 Sep 2021.
- 11 Jan 2016 New trial record